Shares of Aratana Therapeutics Inc. (NASDAQ:PETX) were up 4.5% during mid-day trading on Wednesday . The stock traded as high as $6.82 and last traded at $6.76, with a volume of 289,452 shares changing hands. The stock had previously closed at $6.47.

Several analysts have issued reports on PETX shares. William Blair reaffirmed an “outperform” rating on shares of Aratana Therapeutics in a research report on Tuesday, April 26th. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $11.00 target price on shares of Aratana Therapeutics in a research report on Tuesday, March 22nd. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a research report on Wednesday. Jefferies Group reaffirmed a “buy” rating and set a $12.00 target price on shares of Aratana Therapeutics in a research report on Saturday, April 2nd. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $15.00 target price on shares of Aratana Therapeutics in a research report on Sunday. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $11.66.

The firm’s market capitalization is $238.95 million. The company’s 50 day moving average is $6.67 and its 200 day moving average is $5.27.

Aratana Therapeutics (NASDAQ:PETX) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.10. During the same period last year, the firm earned ($0.26) earnings per share. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.13 million. The business’s revenue was up 6.3% on a year-over-year basis. Equities research analysts expect that Aratana Therapeutics Inc. will post ($1.08) earnings per share for the current year.

In related news, insider Ernst Heinen sold 15,000 shares of the stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $6.72, for a total transaction of $100,800.00. Following the completion of the transaction, the insider now directly owns 125,494 shares of the company’s stock, valued at $843,319.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Julia A. Stephanus sold 30,000 shares of the stock in a transaction dated Tuesday, June 28th. The stock was sold at an average price of $6.25, for a total transaction of $187,500.00. Following the transaction, the insider now directly owns 127,503 shares of the company’s stock, valued at $796,893.75. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Aratana Therapeutics stock. Jennison Associates boosted its stake in Aratana Therapeutics Inc. (NASDAQ:PETX) by 20.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,146,200 shares of the biopharmaceutical company’s stock after buying an additional 714,413 shares during the period. Jennison Associates owned approximately 11.84% of Aratana Therapeutics worth $35,077,000 as of its most recent SEC filing.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.